Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Clearside Biomedical, Inc. (CLSD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
4
| Hutson Nancy J (Director) has filed a Form 4 on Clearside Biomedical, Inc.|
Txns:
| Bought 10,000 shares
@ $0.86, valued at
$8.6k
|
|
| 09/29/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 05/12/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2023 |
8-K
| Quarterly results |
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/02/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...|
Docs:
|
"Presentation",
"Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMD - Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment - - Extension Participants Experienced a 77 - 85% Reduction in Treatment Burden Over 6 Months - - Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Mark R. Barakat, M.D. - ALPHARETTA, Ga., February 2, 2023 - Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , annou..." |
|
| 01/20/2023 |
4
| Ciulla Thomas (Chief Medical Officer) has filed a Form 4 on Clearside Biomedical, Inc.|
Txns:
| Sold 13,700 shares
@ $1.47, valued at
$20.1k
|
|
| 01/20/2023 |
4
| LASEZKAY GEORGE M (CEO) has filed a Form 4 on Clearside Biomedical, Inc.|
Txns:
| Sold 20,030 shares
@ $1.46, valued at
$29.2k
|
|
| 01/20/2023 |
4
| Deignan Charles A. (CFO) has filed a Form 4 on Clearside Biomedical, Inc.|
Txns:
| Sold 14,030 shares
@ $1.5, valued at
$21k
|
|
| 01/11/2023 |
4
| Ciulla Thomas (Chief Medical Officer) has filed a Form 4 on Clearside Biomedical, Inc.|
Txns:
| Sold 2,170 shares
@ $1.62, valued at
$3.5k
|
|
| 01/06/2023 |
4
| LASEZKAY GEORGE M (CEO) has filed a Form 4 on Clearside Biomedical, Inc.|
Txns:
| Granted 487,500 options to buy
@ $1.48, valued at
$721.5k
|
|
| 01/06/2023 |
4
| Deignan Charles A. (CFO) has filed a Form 4 on Clearside Biomedical, Inc.|
Txns:
| Granted 187,500 options to buy
@ $1.48, valued at
$277.5k
|
|
| 01/06/2023 |
4
| Ciulla Thomas (Chief Medical Officer) has filed a Form 4 on Clearside Biomedical, Inc.|
Txns:
| Granted 5,000 shares
@ $1.25, valued at
$6.3k
Granted 5,000 shares
@ $0.95, valued at
$4.8k
Granted 187,500 options to buy
@ $1.48, valued at
$277.5k
|
|
| 01/04/2023 |
SC 13D/A
| Hatteras Venture Advisors III, LLC reports a 6.1% stake in CLEARSIDE BIOMEDICAL, INC. |
| 01/04/2023 |
SC 13G/A
| WHITMORE BRADFORD T reports a 9.9% stake in Clearside Biomedical, Inc. |
| 12/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 11/21/2022 |
4
| Hutson Nancy J (Director) has filed a Form 4 on Clearside Biomedical, Inc.|
Txns:
| Bought 30,000 shares
@ $1.33, valued at
$39.9k
|
|
| 11/09/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
|
|
|